(NP (NP (NN Glucocorticoid) (NN resistance)) (PP (IN in) (NP (JJ chronic) (NN asthma))) (. .))
(NP-COOD (NP (NN Glucocorticoid) (NNS pharmacokinetics)) (, ,) (NP (NN glucocorticoid) (NN receptor) (NNS characteristics)) (, ,) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NN T) (NN cell) (NN proliferation))) (PP (IN by) (NP (NNS glucocorticoids))) (ADJP (FW in) (FW vitro))) (. .))
(S (NP-SBJ-7 (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 37) (ADJP-COOD (ADJP (JJ chronic)) (, ,) (ADJP (JJ severe)) (, ,) (ADJP (JJ nonsmoking))) (JJ asthmatic) (NNS patients)) (PP (IN with) (NP (JJ documented) (JJ reversible) (NNS airways) (NN obstruction)))))) (VP (VBD were) (VP (VBN classified) (NP (-NONE- *-7)) (PP (IN as) (ADJP-COOD (ADJP (JJ glucocorticoid-sensitive)) (CC or) (ADJP (NP (-NONE- *?*)) (JJ -resistant)))) (PP (IN on) (DT the) (NN basis) (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP-COOD (NP (NN FEV1)) (, ,) (NP (NN FVC)) (, ,) (CC and) (NP (NP (JJ peak) (NN expiratory) (NN flow)) (PRN (-LRB- -LRB-) (NP (NN PEF)) (-RRB- -RRB-))))) (PP-TMP (IN after) (NP (JJ oral) (NN prednisolone))))))) (. .))
(S (NP-SBJ (DT The) (JJ resistant) (NNS patients)) (VP (VBD showed) (NP (NP (DT no) (JJ significant) (NNS improvements)) (PP (IN in) (NP (NN airflow) (NN limitation))))) (. .))
(S (NP-SBJ-9 (NP (ADJP (NN Phytohemagglutinin) (-LRB- -LRB-) (NN PHA) (-RRB- -RRB-) (JJ -induced)) (NN proliferation)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes)) (PP (IN from) (NP (NP-COOD (NP (DT the) (JJ sensitive) (NP (-NONE- *RNR*-8))) (CONJP (CC but) (RB not)) (NP (DT the) (JJ resistant) (NP (-NONE- *RNR*-8)))) (NP-8 (JJ asthmatic) (NNS patients))))))) (VP (VBD was) (ADVP (RB significantly) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (ADJP-PRD (ADJP (JJR less)) (PP (IN than) (NP (CD 0.01))))) (-RRB- -RRB-))) (VP (VBN inhibited) (NP (-NONE- *-9)) (PP (IN by) (NP-LGS (NP (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (CD 10-LRB--7-RRB-) (NN (L mol))) (-RRB- -RRB-)))) (, ,) (S (NP-SBJ (-NONE- *)) (VP (VBG reflecting) (NP (NP (DT a) (NN shift)) (PP (IN of) (NP (DT the) (JJ dose-response) (NN curve)))))))) (. .))
(S (SBAR-TMP (WHADVP-200 (WRB When)) (S (NP-SBJ-33 (PDT all) (DT the) (JJ asthmatic) (NNS patients)) (VP (VBD were) (VP (VBN analyzed) (NP (-NONE- *-33)) (ADVP (RB together)) (ADVP (-NONE- *T*-200)))))) (, ,) (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT a) (JJ significant) (NN correlation)) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN sensitivity)) (PP (IN of) (NP (NN T) (NNS cells))) (PP (TO to) (NP (NN dexamethasone)))))) (CC and) (NP (NP (DT the) (JJ clinical) (NN responsiveness)) (PP (TO to) (NP (JJ prednisolone))))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (ADJP-PRD (ADJP (RBR less)) (PP (IN than) (NP (CD 0.01))))) (-RRB- -RRB-))) (. .))
(S (NP-SBJ-10 (DT No) (NNS differences)) (VP (VBD were) (VP (VBN observed) (NP (-NONE- *-10)) (PP (IN between) (NP (NP (CD six)) (PP (IN of) (NP (DT the) (ADJP-COOD (ADJP (JJ sensitive)) (CC and) (ADJP (JJ resistant))) (NNS patients))))) (PP (IN in) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NN plasma) (JJ prednisolone)) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (ADJP (RB orally) (VBN administered)) (NN prednisone)))))))))) (. .))
(S (NP-SBJ-11 (JJ Peripheral) (NN blood) (JJ mononuclear) (NN cell) (NN glucocorticoid) (NNS receptors)) (VP (VBD were) (ADVP (RB also)) (VP (VBN characterized) (NP (-NONE- *-11)) (PP (IN in) (NP (NP-COOD (NP (CD five) (JJ sensitive) (NP (-NONE- *RNR*-12))) (CC and) (NP (CD seven) (JJ resistant) (NP (-NONE- *RNR*-12)))) (NP-12 (NNS patients)))))) (. .))
(S (NP-SBJ (NP (DT The) (NP-COOD (NP (NNS numbers)) (CC and) (NP (NN binding) (NNS affinities)))) (PP (IN of) (NP (DT these) (NNS receptors)))) (VP (MD could) (RB not) (VP (VB account) (PP (IN for) (NP (NP (DT the) (VBN observed) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN susceptibility)) (PP (IN of) (NP (DT these) (NNS cells))) (PP (TO to) (NP (NP (JJ functional) (NN inhibition)) (PP (IN by) (NP (NN dexamethasone))) (ADJP (FW in) (FW vitro)))))))))) (. .))
(S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (JJ clinical) (NN glucocorticoid) (NN resistance)) (PP (IN in) (NP (JJ chronic) (NN asthma)))) (VP-COOD (VP (VBZ does) (RB not) (VP (VB reflect) (NP (JJ abnormal) (NN glucocorticoid) (NN clearance)))) (CC but) (VP (MD may) (VP (VB be) (PP-PRD (JJ due) (ADVP (ADVP (IN at) (JJS least)) (RB partly)) (TO to) (NP (NP (DT a) (JJ relative) (NN insensitivity)) (PP (IN of) (NP (NN T) (NNS lymphocytes))) (PP (TO to) (NP (NNS glucocorticoids))))))))))) (. .))
(S (NP-SBJ (NP (DT This) (NN lack)) (PP (IN of) (NP (NN sensitivity)))) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ unexplained))) (CC but) (VP (VBZ is) (RB not) (ADJP-PRD (JJ attributable) (PP (TO to) (NP (NP (NNS abnormalities)) (PP (IN of) (NP (JJ cellular) (NN glucocorticoid) (NNS receptors)))))))) (. .))
